With increased legalization of marijuana across the United States came increased cases of addiction, and even greater negative outcomes because more of it is smoked.
In a phase 2a clinical study in volunteers with cannabis addiction, a compound named AEF0117, a type 1 cannabinoid receptor signaling-specific inhibitors (CB1-SSi) candidate, produced statistically significant reductions in the positive subjective and reinforcing effects of smoked cannabis.
AEF0117 is discovered and developed by Aelis Farma and based on a natural brain mechanism that combats CB1 receptor hyperactivity.
